Last reviewed · How we verify
Remifentanil automatic
At a glance
| Generic name | Remifentanil automatic |
|---|---|
| Sponsor | Centre Clinical, France |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Automatic Remifentanil Administration Guided by ANI During Propofol Anesthesia (NA)
- Minimal Flow Anesthesia and Infection Risk (NA)
- Automatic Control of Total Intravenous Anesthesia (ACTIVA) (NA)
- Analysis of Clinical Effect of Subanesthetic Dose of Esketamine Combined With Hip Capsule Peripheral Nerve Block in Elderly Patients Undergoing Total Hip Arthroplasty (NA)
- Frail Status of Elderly Patients After Repair and Anesthesia Guided by the bispectraL Index (NA)
- Automated Postoperative Sedation After Cardiac Surgery (NA)
- Automated Anesthesia Guided by the Conox Monitor for Surgery (NA)
- Manual vs Automated Anesthesia : Impact On The Incidence Of POCD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil automatic CI brief — competitive landscape report
- Remifentanil automatic updates RSS · CI watch RSS
- Centre Clinical, France portfolio CI